Novo Nordisk’ chief executive Lars Fruergaard ... be the only industry representative in the GLP-1 agonist market to testify at the hearing. President Donald Trump said he will sign an order ...

Novo Nordisk's (NVO) investors are worried its competition ... according to the latest prescription data last month. But Novo CEO Lars Jørgensen attributes the softness in sales to the copycats ...

Novo Nordisk should look to the US for its next CEO, analysts say As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a ...

Novo Nordisk CEO Lars Jørgensen sits down for an interview with Yahoo Finance senior health reporter Anjalee Khemlani, where they discuss Novo's GLP-1 weight-loss drug Wegovy, the drugmaker's ...

"We’re excited to work with Novo Nordisk, a company known for breakthrough innovation in clinical medicine and a strong portfolio of medications," Hims & Hers CEO Andrew Dudum said in a statement.

"Growth is expected to pick up in the second-half of the year," CEO Lars Fruergaard Jorgensen said on a call with journalists. Novo Nordisk said first-quarter sales of Wegovy were 17.36 billion ...

the company's CEO, Andrew Dudum, told CNBC in an interview. He said he thinks the company's partnership with Novo Nordisk will serve as a case study for how patients get access to and get prices ...

Novo Nordisk (NVO) won a key case Thursday to stop some compounding pharmacies from selling knockoff versions of its blockbuster GLP-1 drugs. But it won't end all compounding offerings.

Drugmaker Novo Nordisk NVO-N expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after ...